Pegaspargase.
L-asparaginase is an antineoplastic agent proven to be effective in depleting the amino acid L-asparagine in patients with childhood and adult acute lymphoblastic leukemia. It has become a significant part of most chemotherapy protocols, however, its use is sometimes limited by the development of hypersensitivity reactions. Pegaspargase offers leukemia patients adequate asparagine depletion with a reduced incidence of hypersensitivity. Other advantages include a longer circulating half-life, increased solubility, and increased resistance to proteolysis, which allows administration of smaller dosages at less-frequent intervals.